Skip to main content

Advertisement

Table 3 Gitelman syndrome (including definite or probable cases) and GHD: cases from the literature

From: Classic Bartter syndrome complicated with profound growth hormone deficiency: a case report

Reference Age, years Sex Mutation GH peak (μg/L) to stimulants IGF-1
[12] 3 M 2614fr/unknown (SLC12A3) <8 (INS), <8 (ARG), <8 (CLN) Not determined
9 F G186D/unknown (SLC12A3) 6 (CLN) 89ng/mL
[5] 3 M Not determined 3.3 (l-DOPA), 7.3 (CLN) 0.26U/mL
9 F Not determined 9.2 (l-DOPA), 4.8 (CLN) 0.67U/mL
19 F Not determined 6.0 (CLN) Not determined
[6] 7 M Not determined 9.8 (INS + ARG) Not determined
[11] 9 M Not determined 2.1 (INS), 3.2 (CLN), 1.8 (l-DOPA) 55ng/mL
[13] 10 F Not determined 7.5 (l-DOPA), 6.9 (CLN) Normal
[14] 11 M Not determined 10.8 (GRF), 7.0 (CLN) 0.43U/mL
[15] 11 M Not determined 5 (INS), 1 (CLN), 13 (GRF) 292ng/mL
[4] 11 M Not determined 11 (CLN), 3.1 (GLC) 0.74U/mL
[16] 13 M Not determined 5.4 (INS), 5.4 (ARG), 12 (GLC-PPL) 0.19U/mL
  1. Cases were categorized as Gitelman syndrome according to the authors’ own judgment, even if they were described as Bartter syndrome in the original reports.
  2. ARG arginine, CLN clonidine, l -DOPA l-3,4-dihydroxyphenylalanine, GH growth hormone, GLC glucagon, GRF growth hormone releasing factor, IGF-1 insulin-like growth factor 1, INS insulin, PPL propranolol.